Related Experiment Video

Updated: Jul 20, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive

Henning Ebelt1, Mirco Jungblut, Ying Zhang

  • 1Department of Medicine III, Martin Luther University, Halle, Germany.

Stem Cells (Dayton, Ohio)
|September 16, 2006
PubMed

Insights

Transplanted skeletal myoblasts and cardiomyocytes improve heart function after myocardial infarction. Their beneficial effects stem from releasing cardioactive cytokines, not cell integration.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Biology
  • Cell Therapy

Background:

  • Cardiac stem cell transplantation shows promise for treating myocardial infarction.
  • The precise mechanisms of cardiac repair post-transplantation remain unclear.
  • Cell differentiation into cardiomyocytes may not be the sole reparative pathway.

Purpose of the Study:

  • To compare the therapeutic effects of skeletal myoblasts and ESC-derived cardiomyocytes after myocardial infarction.
  • To investigate the role of cytokine release in cardiac repair mediated by transplanted cells.
  • To elucidate the mechanisms underlying cell-based cardiac repair.

Main Methods:

  • Implantation of skeletal myoblasts and ESC-derived cardiomyocytes into infarcted mouse hearts.
  • Echocardiographic follow-up and histological analysis to assess cardiac function and tissue architecture.
  • Measurement of cardioactive cytokine secretion by transplanted cells.

Main Results:

  • Both cell types significantly improved left ventricle function and cardiac tissue architecture long-term.
  • Skeletal myoblasts were not detected in infarcted hearts at 28 days post-transplantation.
  • Transplanted cells secreted significant amounts of IL-1alpha, IL-6, TNF-beta, and oncostatin M, promoting cardiomyocyte survival and protein synthesis.

Conclusions:

  • The beneficial effects of cell transplantation for cardiac repair are likely mediated by secreted cardioactive cytokines.
  • Cell integration into the myocardium plays a limited role in the observed functional and morphological improvements.
  • Cytokine release from transplanted cells represents a key mechanism in promoting cardiac regeneration.

More Related Videos

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...